This company has been acquired
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Alimera Sciences Toekomstige groei
Future criteriumcontroles 4/6
Alimera Sciences is forecast to grow earnings and revenue by 62.7% and 16.3% per annum respectively while EPS is expected to grow by 63.1% per annum.
Belangrijke informatie
62.7%
Groei van de winst
63.1%
Groei van de winst per aandeel
| Pharmaceuticals winstgroei | 24.1% |
| Inkomstengroei | 16.3% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 25 Jun 2024 |
Recente toekomstige groei-updates
Recent updates
Alimera Sciences: Deal Closing After All, CVR Still Attractive
Sep 11Alimera Sciences: Cheap CVR Optionality
Jul 16Market Still Lacking Some Conviction On Alimera Sciences, Inc. (NASDAQ:ALIM)
Jun 18
Alimera Sciences, Inc.'s (NASDAQ:ALIM) Shares Not Telling The Full Story
Feb 15Is Alimera Sciences (NASDAQ:ALIM) A Risky Investment?
Dec 30Investors Holding Back On Alimera Sciences, Inc. (NASDAQ:ALIM)
Oct 13Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?
Sep 13Alimera confirmatory trial testing Iluvien in diabetic macular edema patients shows positive data
Oct 06Alimera's eye inflammation Iluvien injection granted reimbursement in Ireland
Sep 20Alimera granted reimbursement in Portugal for eye inflammation Iluvien injection
Aug 09Alimera granted pricing, reimbursement in France for eye inflammation Iluvien injection
Jul 22Alimera gets Italian nod for its Iluvien injection to treat a form of eye inflammation
Jul 08Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?
Mar 24Is Alimera Sciences, Inc. (NASDAQ:ALIM) Worth US$5.7 Based On Its Intrinsic Value?
Nov 06Why Alimera Sciences' (NASDAQ:ALIM) Earnings Are Weaker Than They Seem
Aug 24Alimera Sciences' (NASDAQ:ALIM) Shareholders Are Down 75% On Their Shares
Feb 11Alimera Sciences (ALIM) Investor Presentation - Slideshow
Nov 18Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 136 | 24 | 52 | N/A | 3 |
| 12/31/2025 | 121 | 10 | 37 | N/A | 4 |
| 12/31/2024 | 106 | -7 | 32 | N/A | 4 |
| 6/30/2024 | 100 | -15 | -6 | -6 | N/A |
| 3/31/2024 | 90 | -23 | -88 | -13 | N/A |
| 12/31/2023 | 81 | -21 | -90 | -14 | N/A |
| 9/30/2023 | 68 | -21 | -94 | -18 | N/A |
| 6/30/2023 | 59 | -25 | -86 | -10 | N/A |
| 3/31/2023 | 56 | -17 | -6 | -6 | N/A |
| 12/31/2022 | 54 | -18 | -10 | -10 | N/A |
| 9/30/2022 | 54 | -18 | -15 | -14 | N/A |
| 6/30/2022 | 53 | -17 | -16 | -15 | N/A |
| 3/31/2022 | 60 | -7 | -8 | -7 | N/A |
| 12/31/2021 | 59 | -4 | -4 | -3 | N/A |
| 9/30/2021 | 59 | -1 | 1 | 1 | N/A |
| 6/30/2021 | 59 | 2 | 1 | 2 | N/A |
| 3/31/2021 | 47 | -8 | -6 | -5 | N/A |
| 12/31/2020 | 51 | -5 | -3 | -2 | N/A |
| 9/30/2020 | 54 | -4 | -2 | -2 | N/A |
| 6/30/2020 | 55 | -6 | -4 | -3 | N/A |
| 3/31/2020 | 56 | -9 | -4 | -4 | N/A |
| 12/31/2019 | 54 | -10 | -4 | -4 | N/A |
| 9/30/2019 | 52 | -12 | -4 | -4 | N/A |
| 6/30/2019 | 50 | 19 | -4 | -4 | N/A |
| 3/31/2019 | 50 | 22 | -6 | -6 | N/A |
| 12/31/2018 | 47 | 17 | -12 | -12 | N/A |
| 9/30/2018 | 41 | 11 | -14 | -14 | N/A |
| 6/30/2018 | 39 | -22 | -14 | -14 | N/A |
| 3/31/2018 | 39 | -23 | N/A | -14 | N/A |
| 12/31/2017 | 36 | -22 | N/A | -13 | N/A |
| 9/30/2017 | 37 | -21 | N/A | -14 | N/A |
| 6/30/2017 | 36 | -25 | N/A | -18 | N/A |
| 3/31/2017 | 35 | -29 | N/A | -23 | N/A |
| 12/31/2016 | 34 | -33 | N/A | -25 | N/A |
| 9/30/2016 | 29 | -38 | N/A | -32 | N/A |
| 6/30/2016 | 28 | -30 | N/A | -32 | N/A |
| 3/31/2016 | 24 | -32 | N/A | -37 | N/A |
| 12/31/2015 | 22 | -31 | N/A | -45 | N/A |
| 9/30/2015 | 18 | -30 | N/A | -46 | N/A |
| 6/30/2015 | 14 | -35 | N/A | -42 | N/A |
| 3/31/2015 | 10 | -26 | N/A | -33 | N/A |
| 12/31/2014 | 8 | -37 | N/A | -24 | N/A |
| 9/30/2014 | 8 | -41 | N/A | -25 | N/A |
| 6/30/2014 | 6 | -36 | N/A | -29 | N/A |
| 3/31/2014 | 4 | -58 | N/A | -34 | N/A |
| 12/31/2013 | 2 | -51 | N/A | -38 | N/A |
| 9/30/2013 | 1 | -42 | N/A | -35 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: ALIM is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Winst versus markt: ALIM is forecast to become profitable over the next 3 years, which is considered above average market growth.
Hoge groeiwinsten: ALIM is expected to become profitable in the next 3 years.
Omzet versus markt: ALIM's revenue (16.3% per year) is forecast to grow faster than the US market (8.7% per year).
Hoge groei-inkomsten: ALIM's revenue (16.3% per year) is forecast to grow slower than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if ALIM's Return on Equity is forecast to be high in 3 years time